Observational studyMedicine2025
Predictive value of derived neutrophil-to-lymphocyte ratio for immune checkpoint inhibitor outcomes in advanced gastric cancer.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The derived neutrophil-to-lymphocyte ratio (dNLR) has been suggested as a potential prognostic biomarker for patients undergoing immune checkpoint inhibitor (ICI) therapy, particularly in advanced gastric cancer (AGC). This study aims to evaluate the prognostic value of pretreatment dNLR in AGC patients receiving ICIs. In this retrospective study, 168 AGC patients treated with ICIs at our hospital from January 2015 to December 2019 were included. Patients were grouped based on baseline dNLR levels: high (dNLR ≥ 3) and low (dNLR < 3). Treatment response was evaluated using the response evaluation criteria in solid tumors version 1.1, and progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan-Meier survival analysis. Statistical analyses included Cox proportional hazards regression and log-rank tests to determine the impact of dNLR on survival outcomes. A total of 168 patients with AGC were analyzed. Baseline characteristics were generally balanced between groups, with 22.6% of patients classified as high dNLR (≥3). Treatment response did not significantly differ according to dNLR status: objective response rate was 26.2% in the low dNLR group versus 23.7% in the high dNLR group, and disease control rate was 49.2% versus 44.8%, respectively. In contrast, survival outcomes showed significant differences. Patients with low dNLR had a markedly longer median OS (23.5 vs 15.6 months; hazard ratio = 1.865, 95% confidence interval: 1.216-3.156, P < .001) and median PFS (15.6 vs 8.5 months; hazard ratio = 1.916, 95% confidence interval: 1.213-3.028, P < .001) compared with those with high dNLR. Multivariate Cox regression adjusting for age, Eastern Cooperative Oncology Group score, metastatic burden, and treatment modality confirmed that high dNLR independently predicted poorer PFS and OS. Pretreatment dNLR is a valuable prognostic biomarker for PFS and OS in AGC patients receiving ICI therapy. Patients with lower dNLR levels may achieve more favorable outcomes, underscoring the potential of dNLR in guiding personalized treatment strategies for AGC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.